Cardiovascular: Page 4

QuidelOrtho nabs Health Canada approval for high-sensitivity troponin I test on small-footprint analyzer

By LabPulse.com staff writers

The test, a fluorescence immunoassay, runs on the Quidel Triage MeterPro platform and provides a quantitative determination of troponin I in whole blood or plasma specimens as an aid in the diagnosis of myocardial infarction.

December 20, 2022

Clinical-grade wearables developer Cardiosense raises $15.1M in Series A financing

By LabPulse.com staff writers

The Chicago-based digital health company is leveraging artificial intelligence and multisensor devices to develop tools that enable the early detection of cardiovascular disease.

December 8, 2022

‘Good’ cholesterol worse for some adults: NIH study

By Jared Berberabe

In the study, lower levels of "good" cholesterol were associated with increased risks for heart attacks for white but not Black adults.

November 23, 2022

Physician, medical office to pay more than $2.6M involving clinical lab kickbacks

By LabPulse.com staff writers

Feel Well Health and its owner violated the Anti-Kickback Statute by receiving remuneration from Boston Heart Diagnostics for clinical laboratory services for Medicare patients, according to the DOJ.

November 15, 2022

Roche points to results of heart failure study leveraging its cardiac hormone biomarker and test

By Jared Berberabe

The results were shared this week at an American Heart Association Late-Breaking Scientific Session and published simultaneously in the Lancet.

November 9, 2022

ACC, AHA issue aortic disease guideline, recommend genetic screening

By Jared Berberabe

The guidelines include genetic testing of first-degree relatives of individuals with thoracic aortic disease, as well as an emphasis on surgical thresholds, imaging, and multidisciplinary aortic teams.

November 3, 2022

UK Biobank study links COVID-19 infection with poor cardiovascular health

By Jared Berberabe

Individuals who have been hospitalized because of COVID-19 infection have a higher risk of experiencing adverse cardiovascular health outcomes, according to a UK Biobank study.

October 27, 2022

Epigenetics testing firm Cardio Diagnostics goes public on Nasdaq

By Leo O'Connor

At the core of its cardiovascular solutions is the Integrated Genetic-Epigenetic Engine, developed at the University of Iowa.

October 26, 2022

AI-enabled retina imaging could predict cardiovascular disease, death

By Jared Berberabe

The method could enable the development of a noninvasive test to screen people who are at medium-to-high risk of circulatory disease.

October 14, 2022

Daxor highlights study on test in heart failure management

By LabPulse.com staff writers

Daxor highlighted results of a study from Duke Heart validating the utility of the firm's diagnostic blood test in optimizing the therapeutic management of heart failure patients.

October 3, 2022

Nordic touts PRO-C6 biomarker for heart failure clinical trials

By LabPulse.com staff writers

In collaboration with Bristol Myers Squibb and the University of Pennsylvania, researchers combined analyses of six independent cohorts of HFpEF patients from around the globe, which are being evaluated with the PRO-C6 biomarker.

September 13, 2022

Boston Heart Diagnostics launches polygenic risk map

By LabPulse.com staff writers

The risk map leverages polygenic risk scores (PRS) to provide physicians with an understanding of a patient's absolute genetic risk of complex disease, allowing for the creation of early, personalized intervention strategies, the firm said.

September 12, 2022

Previous Page

Page 4 of 8

Next Page